Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination

Table 2 Global HPV type distribution in cervical ADC (including ASC)

HPV type	Li et al., 2011¹	de Sanjosé et al., 2010²	Weighted average of both studies
Number of cases	3525³	951	-
HPV positive cases, n (%)	2891 (82.0%)	624 (65.6%)	-
HPV prevalence among HPV positive cases (%)
6	0.1	0.2	0.1
11	0.1	0.0	0.1
16	40.0	47.4	41.6
18	40.5	32.2	38.7
26	0.0	0.0	0.0
30	0.0	0.2	0.0
31	2.5	1.0	2.2
33	2.4	1.0	2.1
34	0.0	0.0	0.0
35	0.7	0.6	0.7
39	0.9	0.8	0.9
40	NT	0.0	-
42	NT	0.0	-
43	NT	0.0	-
44	NT	0.0	-
45	5.7	11.8	7.0
51	0.7	0.6	0.7
52	1.3	0.2	1.1
53	0.2	0.2	0.2
54	NT	0.0	-
56	0.2	0.3	0.2
58	1.7	0.5	1.4
59	0.9	0.8	0.9
66	0.1	0.2	0.1
67	0.2	0.0	0.2
68	0.6	0.3	0.5
69	0.9	0.0	0.7
70	0.2	0.0	0.2
73	0.0	0.0	0.0
74	NT	0.0	-
82	0.1	NT	-
85	0.0	NT	-
Undetermined	NR	1.3	-

ADC, adenocarcinoma; ASC, adenosquamous carcinoma; NR, not reported; NT, not tested. ¹We adjusted prevalence rates from those reported by Li et al. [29] to indicate the HPV type-specific contribution to the total number of positive samples. In addition because women infected with multiple types contribute multiple times in the numerator but only once in the denominator, the addition of the total percentages exceeded 100; therefore we also adjusted these estimates to sum to 100%. ²de Sanjosé et al. [30] reported prevalence rates for ADC and ASC separately; we have added the estimates together to give an estimate of type-specific prevalence for ADC (including ASC). Prevalence rates indicate the HPV type-specific contribution to the total number of positive samples. Multiple infections were added to single types through proportional weighting attribution. ³HPV positivity data reported for only 3,525 of the 3,538 total cases of ADC.

ISSN: 1471-2407